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sTNFRSF = soluble TNF recepBACKGROUND: Chronic respiratory symptoms and exacerbation-like events are common among
ever-smokers without airflow limitation on spirometry. The pathobiology of respiratory disease in
this subgroup remains poorly defined, but may be due to underlying inflammation that overlaps
with COPD or asthma. We hypothesized that symptoms, exacerbations, and functional measures
of disease severity among smokers with preserved spirometry would be associated with markers
of systemic inflammation, similar to what is reported in bone fide COPD, rather than elevated
type 2 inflammation, which is often present in asthma.
METHODS: We measured inflammatory markers associated with COPD (C-reactive protein
[CRP], fibrinogen, soluble tumor necrosis factor receptors [sTNFRSF1A and sTNFRSF1B],
and blood/sputum neutrophils) and type 2 inflammation (IgE and blood/sputum eosino-
phils) in smokers with preserved spirometry (postbronchodilator FEV1/FVC $ 0.70) from
the Subpopulations and Intermediate Outcome Measures In COPD Study (SPIROMICS). We
evaluated the relationship of these markers with respiratory symptom burden (dichotomized
by a COPD assessment test score cutoff of 10, diagnosis of chronic bronchitis), exacerbations,
6-minute walk distance, and lung function on the basis of FEV1.
RESULTS: CRP was associated with increased symptom burden (on the basis of COPD assess-
ment test score and diagnosis of chronic bronchitis) and a greater number of exacerbations in the
year before study enrollment. sTNFRSF1A was associated with symptom burden on the basis of
COPD assessment test score. CRP and sTNFRSF1A levels negatively correlated with 6-minute
walk distance. IgE and eosinophils were not associated with these outcomes.
CONCLUSIONS: Markers of inflammation including CRP and sTNFRSF1A are enriched
among symptomatic smokers with preserved spirometry, suggesting an overlap with the
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COPD is a heterogeneous respiratory condition that is a
leading cause of morbidity and mortality worldwide. A
postbronchodilator FEV1/FVC ratio < 0.70 is required
to confirm a COPD diagnosis.1 There is compelling
evidence, however, that this diagnostic cutoff fails to
capture the full breadth of smoking-related airway
disease. Epidemiologic data from our group and others
suggest that chronic respiratory symptoms are common
among current and former smokers with preserved
FEV1/FVC ratios ($ 0.70).
2,3 These symptoms are
associated with higher rates of COPD-like exacerbations,
evidence of occult airway disease signified by reduced
lung function, airway wall thickening on CT scan, a
higher prevalence of chronic bronchitis, and elevated
sputum mucin concentration.3,4
The underlying processes leading to symptoms and
pathologic changes in these smokers with preserved
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DOI: https://doi.org/10.1016/j.chest.2018.12.022mechanisms underlying this condition may be similar to
those in COPD with confirmed airflow limitation and
manifest as elevations in systemic biomarkers classically
associated with COPD. Alternatively, type 2
inflammation, a predominant component of asthma,5
may be enhanced in this group, and manifest as
elevations in biomarkers of type 2 inflammation. It is
difficult to establish the contribution of asthma-like
pathology to disease in this population of smokers at
high risk for developing COPD. Furthermore, we have
shown that type 2 inflammation can occur in COPD
even without a prior diagnosis of asthma.6
To test these two competing hypotheses, we profiled blood
and sputum inflammatory markers in ever-smokers with
preserved spirometry in the Subpopulations and
Intermediate Outcome Measures in COPD Study
(SPIROMICS),7 from which we originally characterized the
clinical significance of symptoms in this smoking
population.3 We a priori selected inflammatory markers
associated with COPD (including serum C-reactive protein
[CRP], fibrinogen, soluble tumor necrosis factor [TNF]
receptors, and blood/sputum neutrophils),8,9 and markers
of type 2 inflammation (including IgE and blood/sputum
eosinophils). We related these markers to symptom
burden, exacerbations, and functional measures of disease
severity.
Methods
Study Participants and Definitions
We used data from 830 ever-smokers with preserved spirometry enrolled
in SPIROMICS, a longitudinal prospective cohort study.7 We defined
preserved spirometry as an FEV1/FVC ratio $ 0.70, and an FVC greater
than or equal to the lower limit of normal. We categorized participants
as symptomatic using the COPD assessment test (CAT), a validated
eight-question health status tool,10 and by a study-defined diagnosis of
chronic bronchitis. Consistent with our previous analyses and the Global
Initiative for Chronic Obstructive Lung Disease criteria, we categorized
participants with a CAT score $ 10 as symptomatic.1,3 We defined
chronic bronchitis as self-reported cough and phlegm on most days for
at least 3 months per year, over a period of 2 years or more.11 We
collected data on self-reported exacerbations retrospectively over the year
before enrollment and prospectively over the study period. We defined
exacerbations as the use of antibiotics, systemic glucocorticoids, and/or a
health-care utilization event (office visit, ED visit, or hospitalization) for
a respiratory symptom “flare-up.” Historical data regarding asthma
diagnoses were defined as “childhood asthma” for childhood diagnoses
and “ever-asthma” encompassing both childhood and adult diagnoses.
Participants with unstable cardiac disease were excluded. We collected
information on comorbid cardiovascular conditions including
hypertension, coronary artery disease, congestive heart failure, valve
disease, and vascular disease. The study protocol was approved by the
institutional review boards of all participating sites. All participants gave
written informed consent. Additional details regarding the study
protocol and institutional review board documentation are available in
e-Appendix 1 and e-Table 1.
Inflammatory Marker Measurements and Normalization
Procedure
We collected complete blood counts with differential, sputum cell
differential counts, and enzyme-linked immunosorbent assay-based
measurements of serum IgE in all participants. We measured CRP,
fibrinogen, and the soluble TNF receptor superfamily (sTNFRSF)
members 1A (also known as sTNF-R55) and 1B (also known as
sTNF-R75) in a subset of samples using Luminex-based multiplex
assays (n ¼ 429).12,13 Raw measurements were log transformed and
normalized by z score (e-Appendix 1).
Statistical Analyses
We compared demographic and clinical characteristics across groups
using t tests and c2 tests as appropriate. We fit logistic regression
models to assess the relationships between inflammatory markers
and symptoms. We used Wilcoxon rank sum tests to evaluate rawmarker values and negative binomial regression to evaluate
associations between inflammatory marker levels and exacerbations.
Prospective exacerbations were modeled with an offset term of the
natural log of total follow-up time to accommodate for variable
follow-up time across participants. We fit linear regression models to
relate inflammatory marker levels to 6-minute walk test distance
(6MWD) and postbronchodilator percent of predicted FEV1. Adjusted
multivariate models were fit with age, sex, BMI, race, current smoking
status, smoking pack-years, baseline asthma history, study site, and assay
batch as covariates. We used analysis of variance to evaluate differences
in CRP between study strata, and Tukey-Kramer tests to evaluate
pairwise comparisons. We compared baseline CRP measurements to 1-
year follow-up measurements using Pearson correlation and Bland-
Altman analyses. We defined statistical significance as P < .05. False
discovery rate adjusted P values were calculated using the Benjamini-
Hochberg procedure.14Results
Characteristics of Study Participants
Among ever-smokers without airflow limitation (n ¼ 
830), 415 were symptomatic (CAT $ 10) (Table 1). 
Symptomatic participants were younger, had a higher 
average BMI, slightly lower lung function, and a 
marginally higher response to bronchodilators relative 
to participants without symptoms. A higher percentage 
of participants with symptoms were women, African 
American, and current smokers. The pack-year smoking 
history was higher among symptomatic participants. 
Symptomatic participants were more likely to have a 
history of asthma in both childhood and ever. There was 
no significant difference in FEV1/FVC ratio between 
these groups. Among the ever-smokers with preserved 
spirometry, 149 had chronic bronchitis. Participants 
with chronic bronchitis were younger, more likely to be 
current smokers, and more often had a history of asthma 
(ever). Lung function was slightly lower among 
participants with chronic bronchitis.
Associations of Inflammatory Markers With 
Symptoms
In unadjusted analyses, CRP and IgE were associated 
with increased odds of having symptoms defined by 
CAT score (Table 2). In adjusted analyses, CRP 
remained associated with worse symptoms (OR, 1.30; 
95% CI, 1.03-1.65; P ¼ .03). The median raw CRP level 
among symptomatic participants was 3.6 mg/mL
(interquartile range [IQR], 1.4-8.1) compared with 2.0 
mg/mL (IQR, 0.8-4.8) among participants without 
symptoms (P < .001) (Fig 1). Including history of 
cardiovascular disease as a model covariate did not affect 
the association between CRP and symptoms (OR, 1.30; 
95% CI, 1.02-1.66; P ¼ .03). sTNFRSF1A was associated 
with symptoms in adjusted analyses only (OR, 1.33;95% CI, 1.03-1.75; P ¼ .03). African American
participants, who were more likely to be symptomatic
(Table 1), had higher median IgE and lower median
sTNFRSF1A levels compared with non-Hispanic white
participants (e-Fig 1). Analyses stratified by race
revealed no differences in IgE between symptomatic and
asymptomatic participants (e-Fig 1A); however, higher
sTNFRSF1A was associated with symptoms across both
race strata (e-Fig 1B). This suggests that race
confounded the relationship between IgE and symptom
status, and negatively confounded the relationship
between sTNFRSF1A and symptom status, explaining
the effects of adjustments in models evaluating these
markers. We assessed the possibility that including
baseline asthma as a covariate in adjusted models
attenuated the association between IgE and respiratory
symptoms. In adjusted analyses with asthma history
(ever) omitted as a covariate, IgE was still not
significantly associated with symptoms (OR, 1.12;
95% CI, 0.95-1.32; P ¼ .18). We next evaluated the effect
of current smoking intensity on the associations among
CRP, sTNFRSF1A, and symptom status. In adjusted
models with current smoking treated as a continuous
variable (number of cigarettes smoked per day), both
CRP and sTNFRSF1A remained associated with
symptoms (CRP: OR, 1.30; 95% CI, 1.03-1.65; P ¼ .03,
sTNFRSF1A: OR, 1.36; 95% CI, 1.06-1.78; P ¼ .02).
In unadjusted analyses, CRP and blood neutrophil
count were associated with increased odds of having
chronic bronchitis. Following adjustments, CRP
remained associated with chronic bronchitis (OR, 1.94;
95% CI, 1.36-2.81; P < .001). The median CRP value
was higher among participants with chronic bronchitis
compared with those without chronic bronchitis (5.9
mg/mL [IQR, 1.7-10.8] vs 2.4 mg/mL [IQR, 1.0-5.6], P <
.001) (Fig 1).













n ¼ 149 P Value
Age, y 61  9.5 59  9.8 < .001 60  9.6 59  9.7 .03
BMI 28  4.7 30  5.1 < .001 29  5.1 29  4.9 .56
Women 199 (48) 236 (57) .01 337 (51) 88 (59) .08
Race
White 322 (78) 231 (56) < .001 443 (67) 102 (69) .94
African American 72 (17) 158 (38) 179 (27) 39 (26)
Other 21 (5) 26 (6) 38 (6) 8 (5)
Current smokers 173 (42) 254 (62) < .001 316 (48) 100 (68) < .001
Smoking, pack-y 40  20 45  29 .008 42  26 45  20 .11
History of asthma, ever 30 (7) 102 (26) < .001 90 (14) 36 (27) < .001
History of childhood
asthma




218 (53) 266 (64) .001 374 (57) 96 (65) .09
Chronic bronchitis 21 (5) 128 (32) < .001
CAT $ 10 272 (41) 128 (86) < .001
Post-BD FEV1
% predicted
100  12 96  13 < .001 99  13 95  12 < .001
FEV1/FVC 0.77  0.05 0.77  0.05 .50 0.77  0.05 0.77  0.05 .50
% BD reversibility 6.0  5.3 7.0  8.1 .03 6.3  6.4 7.0  8.2 .32
CRP, mg/mL 2.0 [0.8-4.8] 3.6 [1.4-8.1] < .001 2.4 [1.0-5.6] 5.9 [1.7-10.8] < .001
Fibrinogen, mg/mL 4.8 [4.3-5.7] 5.0 [4.3-5.9] .23 4.8 [4.2-5.8] 5.1 [4.5-6.2] .07
sTNFRSF1A, ng/mL 1.6 [1.3-2.1] 1.7 [1.3-2.2] .27 1.7 [1.3-2.1] 1.6 [1.3-1.9] .19
sTNFRSF1B, ng/mL 6.5 [5.4-8.3] 7.0 [5.5-8.8] .18 6.8 [5.5-8.6] 6.5 [5.3-8.8] .72
IgE, IU/mL 35 [13-99] 49 [17-156] .001 37 [13-132] 58 [19-129] .06
Blood
neutrophils, 109/L










Sputum neutrophils, % 66 [40-83] 66 [43-80] .86 66 [43-81] 65 [41-82] .95







Clinical and demographic data are reported as mean  SD or No. (%). Inflammatory markers are reported as median [interquartile range]. Participants
with and without symptoms were compared using t tests for continuous variables and c2 tests for categorical variables. CAT ¼ COPD assessment test;
CRP ¼ C-reactive protein; % BD reversibility ¼ percentage improvement in FEV1 following bronchodilator administration; post-BD FEV1 ¼ post-
bronchodilator FEV1; sTNFRSF ¼ soluble tumor necrosis factor receptor superfamily.Associations of Inflammatory Markers With 
Exacerbations
We next investigated the relationship between 
inflammatory marker levels and exacerbations (Table 3). 
A total of 109 study participants had at least one 
exacerbation during the year before enrollment, with 
171 exacerbations reported in total (e-Table 2). In 
unadjusted analyses, CRP and IgE were associated with 
retrospective exacerbations (Table 3). Followingadjustments, only CRP remained associated with
retrospective exacerbations (incidence rate ratio [IRR],
1.40; 95% CI, 1.03-1.92; P ¼ .04). CRP remained
associated with past exacerbations when history of
cardiovascular disease was included as an adjusted
model covariate (IRR, 1.40; 95% CI, 1.03-1.94; P ¼ .04).
In adjusted analyses with asthma history (ever) omitted




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1 – CRP levels across participants with and without symptoms.
Higher CRP levels were associated with respiratory symptoms defined by
CAT score and diagnosis of chronic bronchitis. Box and whisker plots
show median  interquartile (IQR) range. Horizontal lines represent the
median value. The lower and upper limits of the rectangular box
represent the 25th and 75th percentiles. The lower and upper limits of the
whiskers represent the upper and lower quartiles  1.5 times the IQR.
Outliers are shown as points. ***P < .001, calculated using the Wilcoxon
rank sum test. CAT¼ COPD assessment test, CB ¼ chronic bronchitis.Over the study enrollment period, 151 participants
reported at least one exacerbation, with 330 reported in
total. CRP was associated with prospective exacerbations
in unadjusted analyses only (unadjusted IRR, 1.52;
95% CI, 1.13-2.05; P ¼ .005; adjusted IRR, 1.26; 95% CI,
0.88-1.80; P ¼ .15).
Associations of CRP and sTNFRSF1A With Measures
of Disease Severity
We next evaluated whether markers associated with
symptoms were also associated with functional measures
of disease severity such as 6MWD and FEV1 (e-Table 3).
In adjusted analyses, CRP (b ¼ –11.4; 95% CI, –19.7 to
–3.1; P ¼ .007) and sTNFRSF1A (b ¼ –12.2; 95% CI,
–21 to –3.4; P ¼ .007) were negatively correlated with
6MWD. These markers were not associated with FEV1
in adjusted analyses.
CRP Levels Among Never Smokers and Across Time
CRP demonstrated a consistent pattern across multiple
outcomes, prompting us to evaluate comparisons with
never-smoker healthy control patients, and its stability
over time. The median CRP level was higher among
symptomatic (CAT $ 10) smokers with preserved
spirometry compared with never-smoker control
patients (3.6 mg/mL; IQR, 1.4-8.1 vs 1.7 mg/mL; IQR,
0.9-4.0; P < .001), but was not significantly higher in
smokers with preserved spirometry without symptoms
(2.0 mg/mL; IQR, 0.8-4.8 vs 1.7 mg/mL; IQR, 0.9-4.0; P ¼
.36). CRP levels among symptomatic smokers with













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































symptomatic participants with GOLD I or II COPD
(Fig 2). Of the 175 never-smokers in SPIROMICS, 28
reported a CAT score > 10. Among never-smokers,
CRP was not significantly associated with symptoms
(unadjusted OR, 1.38; 95% CI, 0.89-2.21; P ¼ .15;
adjusted OR, 0.89, 95% CI, 0.89-2.21; P ¼ .74). We
assessed the stability of CRP over time among a subset of
smokers with preserved spirometry with 1-year follow-
up measurements available (n ¼ 115). Among these
participants, baseline levels of CRP correlated with 1-
year follow-up levels (r ¼ 0.67, P < .001) (Fig 3).
Discussion
COPD is heterogeneous, with some patients exhibiting
persistent systemic inflammation,15 including elevations
in blood inflammatory proteins such as CRP. Other
patients with COPD display enhanced type 2
inflammation, including lung and blood eosinophilia.16
The relative contribution of systemic vs type 2
inflammation to disease burden among smokers with
preserved spirometry remains uncertain. We
demonstrate that markers of systemic inflammation,
including CRP and sTNFRSF1A, are associated with
respiratory symptoms, exacerbations, and activity
limitation among ever-smokers who do not meet the
current spirometric definition of COPD. Although
symptomatic smokers with preserved spirometry are
more likely to carry an “asthma” diagnosis, we find that
markers of type 2 inflammation including IgE and
blood/sputum eosinophils do not fully explain potential
respiratory disease among this group. A subset of
symptomatic smokers with preserved spirometry may
have a response to smoke exposure that is pathologic
and marked by systemic markers of inflammation that
are classically associated with COPD.
Although CRP and sTNFRSF1A were associated with
worse respiratory symptoms, their sources and
relationships with possible ongoing pulmonary
inflammation remain unclear. These markers may
represent pulmonary inflammation that has “spilled”
into systemic circulation17; however, data supporting
this hypothesis in COPD are controversial because some
studies have failed to demonstrate associations between
inflammatory markers in the lung and plasma.17,18
Alternatively, systemic responses to smoke exposure
may reflect an underlying predisposition toward
developing inflammation, a hypothesis that may help
explain why COPD is frequently associated with
complex inflammatory comorbidities such as metabolic














































Figure 3 – Stability of log transformed CRP measurements over time
among smokers with preserved spirometry. A, Baseline CRP measure-
ments are significantly associated with 1-year follow-up measurements
(n ¼ 115). B, Bland-Altman plot showing mean difference in CRP
measurement from baseline to 1-year follow-up against the mean of the
two measurements. Blue dashed line: overall mean difference between
baseline and follow-up measurements, red dashed lines:  one standard



















Figure 2 – Log transformed CRP levels across healthy participants and 
ever smokers with and without COPD. The median CRP level is higher 
among symptomatic smokers with preserved spirometry and symptom-
atic participants with COPD compared to their asymptomatic coun-
terparts and never-smoker healthy control participants. Box and whisker 
plots show median  interquartile (IQR) range. Horizontal lines 
represent the median value. The lower and upper limits of the rectan-
gular box represent the 25th and 75th percentiles. The lower and upper 
limits of the whiskers represent the upper and lower quartiles  1.5 
times the IQR. Outliers are shown as symbols. ***P < .001, calculated 
using the Tukey-Kramer method.markers of inflammation21 and induce symptoms via
irritation and increased mucus production. Markers of 
inflammation remained associated with increased 
symptoms even after adjustments for current smoking
status, suggesting that current smoking does not fully 
explain the burden of symptoms and exacerbations
among these participants. There is a well-characterized
association between CRP and cardiovascular disease,22
and it is possible that respiratory symptoms in our data
actually reflects underlying cardiac disease rather than
respiratory disease. We demonstrate, however, that the 
association between CRP and respiratory symptoms is 
independent of cardiovascular comorbidities that are
assessed historically.
Higher levels of CRP were associated with chronic
bronchitis in this study. Chronic bronchitis is a hallmark 
feature of COPD, but is also common among current
and former smokers without airflow limitation.11
Features believed to be central to chronic bronchitis
include goblet cell metaplasia,23 leading to mucus 
overproduction and hypersecretion, increased airway
mucin concentration,4 and reduced mucus clearance.11
These pathologic changes can arise from cigarette smokeexposure, infection, and immune cell-mediated
processes.11 CRP was associated with chronic bronchitis
even after adjusting for current smoking status;
furthermore, participants with signs of an acute
pulmonary infection were excluded from SPIROMICS,
suggesting that chronic inflammatory processes underlie
the symptoms of bronchitis in this group.
In COPD, CRP has been shown to predict exacerbations
both as an independent marker24 and when
simultaneously elevated with fibrinogen and leukocyte
count.25 There remains a lack of consensus on the utility
of CRP for exacerbation prediction in COPD, however, 
because CRP did not predict prospective exacerbations in 
an analysis of participants from the Genetic Epidemiology 
of COPD (COPDGene) and SPIROMICS cohorts.26 
Among these previously uncharacterized unobstructed 
participants, we found that CRP was independently 
associated with exacerbations retrospectively but not 
prospectively. This raises the possibility that CRP reflects 
recent exacerbations in our data; however, CRP 
measurements in this study were obtained at least 6 weeks 
after the participants’ last reported exacerbation.
CRP and sTNFRSF1A were associated with shorter 
6MWD, which is concordant with prior studies 
evaluating the relationship between CRP and functional 
limitation in COPD.27-29 CRP was not associated with 
FEV1; however, there was a narrow range of FEV1 values 
among these unobstructed participants.
There are limitations to this report. SPIROMICS was not 
population based, and may have recruited a biased 
proportion of current and former smokers who have 
symptoms in the absence of airflow limitation on 
spirometry. Further validation in population-based 
studies is needed to ensure generalizability. There were 
some technical challenges. Additional markers, 
including IL-6, IL-8, and TNF-a, could not be 
characterized because of poor assay performance. 
Sputum cell differential data were only available in a 
subset of participants because of oral contamination (> 
80% squamous cells) and failed cell differential stains.
In summary, among smokers with preserved 
spirometry, CRP and sTNFRSF1A were associated withclinical evidence of airway disease including respiratory
symptoms, chronic bronchitis, exacerbations, and
activity limitation. Our findings suggest that these
systemic markers reflect the presence of underlying
inflammation that is pathologic and similar to what
occurs in a subset of patients with COPD. This adds to
the growing body of evidence that smoking-related
airway disease extends beyond the spirometric
definition of COPD, potentially representing a
continuum with common pathobiologic features. It
remains unclear whether symptomatic smokers with
preserved spirometry are in an early stage of disease
that will eventually progress to overt COPD with
airflow limitation or whether they have a different
stable smoking-related condition with similar
underlying inflammation.30 If it is the former, then
this may be a group to target with disease-modifying
interventions that prevent disease progression. A
recent study of lung tissue samples found that in mild
to moderate COPD there is a substantial loss of small
airways, undetectable on clinical CT and independent
of emphysema.31 Extensive structural pathology may
be therefore present in COPD before significant lung
function decline is even identified. As current
diagnostics cannot identify these changes, the use of
other strategies (eg, biomarkers and clinical
symptoms as examined in the present study) to
identify the patients that may benefit from early
disease-modifying therapies will likely be necessary.
Overall, this also highlights the need for longitudinal
studies evaluating the clinical and biological trajectory
of symptomatic ever-smokers to better characterize
the natural history of their disease.
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